1. Scrip
  2. >>Leadership

Gilead's R&D Leadership Change Is End Of Bischofberger Era

 
• By Mandy Jackson

Norbert Bischofberger has been with Gilead almost since its beginning and helped the company establish dominance in HIV and hepatitis C, but leaves as it's starting to build franchises in oncology and inflammation. Gilead veterans John McHutchinson and Andrew Cheng are elevated in his place.

Watch gears up close

Gilead Sciences Inc. Executive Vice President-Research & Development and Chief Scientific Officer Norbert Bischofberger is moving on – though where he is going is not clear – after nearly three decades and the establishment of two multibillion-dollar franchises in HIV and hepatitis C.

Bischofberger leaves the R&D pipeline in the hands of two Gilead veterans as the company works to diversify its holdings: Executive Vice President-Clinical Research John McHutchison will be appointed chief scientific officer and assume responsibility for the R&D organization, while Executive Vice President-Clinical Research & Development

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Scrip

Finance Watch: Funding Alternatives Become The Norm In Tough Public Markets

 
• By Mandy Jackson

Public Company Edition: With fewer follow-on offerings, drug developers are pursuing other options. Axsome accessed up to $570m in debt, Evolus obtained $250m in a new credit facility and Abeona raised $155m from a PRV sale, but Apimeds was able to execute a small $13.5m IPO.

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

 
• By Alaric DeArment

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.